WuXi Advanced Therapies is a global CTDMO (Contract Testing, Development, and Manufacturing Organization) that provides services to enable the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Self-described as one of the top 3 in its field.

WuXi Advanced Therapies

WuXi Advanced Therapies provides contract testing, development, and manufacturing services for cell and gene therapies. The company enables the discovery, development, testing, manufacturing, and commercialization of these therapies.

WuXi Advanced Therapies | 14,682 followers on LinkedIn. An integrated cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) | WuXi Advanced Therapies - Accelerating Progress and Time to Market


WuXi Advanced Therapies is a cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability.

Our Story
By leveraging platforms and integrated testing our team provides expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models.

Global Talent Acquisition Leader - US & EU

Mike Quinn, M.S.

Advanced Therapies Consulting and Advisory Services

Alan Moore

Human Resources Director at WuXi Advanced Therapies

Elise Saunders

IT Infrastructure Management | IT Service Delivery | Team Building | Project Management

Cesar Fernandes, PMP

🌟 Meet WuXi Advanced Therapies at Advanced Therapies USA! 🌟 We’re excited to announce that WuXi Advanced Therapies will be exhibiting at Booth #200 at the upcoming Advanced Therapies USA event here in our hometown at the Philadelphia Convention Center! Join us to connect with our team of subject matter experts and senior business development leaders, who are eager to discuss potential partnerships across the cell and gene therapy landscape. Whether you’re looking for support in testing, development, or manufacturing, our team is here to help you accelerate your advanced therapy solutions and bring life-saving innovations to patients worldwide. 📅 Event Date: November 12-13 📍 Booth: #200 Let’s explore how we can work together to advance the future of cell and gene therapy! Aaron Small , Amy Lamperti , Athenesia Faggins, Ph.D. , Audrey Chang , Bianca Williams , Dhaval Gandhi , Heather Malicki, Ph.D. , JJ Sheehan , Joseph Newcome , Jordan Lovett , Linda Zhou, Scott Kelly , Simona Jusyte , Umesh Kishnani , Veronica Ortiz-Suarez , Yuxiang Huang #WuXiAdvancedTherapies #AdvancedTherapiesUSA #CellandGeneTherapy #Biotech #Partnerships #Innovation #CelliconValley

📣 Join Us at Cell 2024! Exciting news from OXGENE ! Maria Inês Patrício , Group Leader in Cell Line Development, will be presenting XOFLX™ Stable Cell Lines – A Flexible Platform for Lentiviral Vector Production at OxfordGlobal Conferences UK #CELL2024 event happening November 6-8 in London. Discover how our innovative XOFLX™ platform offers consistent, high-titre LVV production equivalent to the 4-plasmid process, demonstrating exceptional flexibility with a range of cargo genes and promoters. 🗓 Date: Thursday, November 7 ⏰ Time: 14:45 📍 Location: Track 5, Cell UK Event Whether you're aiming to streamline your lentiviral vector workflows or enhance production consistency, you won’t want to miss this session. See how the XOFLX™ platform could advance your product development lifecycles! #CellUK #CellAndGeneTherapy #OXGENE #LentiviralVectorProduction #XOFLX #Biotechnology #GeneTherapy

We’re thrilled to celebrate Interius BioTherapeutics as they announce the dosing of the first patient in their pioneering in vivo chimeric antigen receptor (CAR) gene therapy clinical trial for B-cell malignancies. This achievement brings the industry one step closer to more accessible and transformative therapies for patients battling cancer. Read the official press release here https://lnkd.in/ezvYT_Av This innovation marks a significant leap in the journey of gene therapy, moving the needle forward on in vivo therapies that could address unmet medical needs for cancer patients worldwide. We are proud to support Interius BioTherapeutics in their mission to reimagine cancer treatment by bringing next-gen CAR therapies directly to patients, expanding the horizon of cell and gene therapy possibilities. Congratulations to the entire Interius BioTherapeutics team on reaching this inspiring milestone, and we look forward to continued progress together as we build a healthier world! #CellandGeneTherapy #WuXiAdvancedTherapies #InteriusBiotherapeutics #GeneTherapy #HealthcareInnovation #BcellMalignancies #InVivoCAR

What do you think are the most common and unique challenges for #techtransfer of advanced therapies? Brandon Haigh lists 7 we encounter most often in the article Tech Transfer: Seven Unique Challenges for Advanced Therapeutics. Read it here https://lnkd.in/e6ctkfZD

Don’t miss Jordan Lovett and Simona Jusyte on tomorrows Outsourced Pharma 's Outsourced Pharma Capacity Update as they discuss the capacity and services available at our site in the #NavyYard in #Philadephia (aka #celliconvalley ) Learn about our clinical and commercial manufacturing capabilities as well as our analytical method development and testing services – available not just for #CGT but also for #mAbs and #viralvaccines . Our testing services are also utilized by both our manufacturing clients and those that manufacture elsewhere. If you haven’t already, register today! https://lnkd.in/efVH27hP This webinar series features multiple manufacturing partners for #CGT . We are presenting in the morning session.

If you are in Rome for #ESGCT don't miss the chance to meet up with our colleagues from OXGENE !

If you are in #Rome this week for The European Society of Gene and Cell Therapy 31st Congress, look for our team on site! We have a whopping 7 posters featuring our #XOFLX ™ Packaging and Producer Cell Lines for Lentiviral Manufacturing and our #TESSA ® Technology and platform which will be presented during the week. Our colleagues from OXGENE will be presenting on the following topics: -- Infectivity measurements of AAV vectors using TESSA-Rep Enabled AAV titration (TREAT) Chloé Fustinoni -- XOFLX™ stable cell lines: a flexible platform for lentiviral vector production Matthew Tridgett -- Process development to enhance cost-saving benefits of XOFLX™ Packaging and Producer Cell Lines for lentiviral vector manufacturing Qian Liu -- Development of a highly reliable and specific assay for determining infectious titre of lentiviral vectors Daniel Blakemore -- Scalable and efficient production of Tetracycline-enabled self-repression adenoviral (TESSA®) vectors to support AAV gene therapy manufacture Adam Dooner -- Promoter Screening to Enhance Scalable Recombinant AAV Manufacture from TESSA® Technology Cristina Andrea Araújo Cuevas -- TESSA® Platform for Transforming Scalable and Versatile Recombinant AAV Gene Therapy Production Weiheng Su Check out the schedule below for details and visit https://lnkd.in/eHeZW6cz to schedule a time to meet!

Congratulations to BridgeBio on their recent publication in Molecular Therapy featuring data from work done using the #TESSA AAV platform. See below for a link to the full article.

On Thursday Oct 24th at 10am EST WuXi Advanced Therapies, will share an update on our capabilities and capacity in Outsourced Pharma 's Capacity Update for #CellandGeneTherapy . During this webinar, CDMOs like us will share their current capacity, capabilities, facility locations, and timelines to help you find the right partner for your next project. Attendees will experience quick, digestible presentations with live Q&A and get a closer look at the available capacity of top industry suppliers. This event is ideal for CGT developers with an active pipeline and industry consultants who help those developers with their strategic sourcing decisions. Register for access to all sessions (live and archived) – and yes, registration is free! Simona Jusyte and Jordan Lovett will present our testing, development, and manufacturing capabilities. https://lnkd.in/efVH27hP

Our team from WuXi Advanced Therapies, including Aaron Small , Simona Jusyte and Peter Colbourne are excited to be attending the Alliance for Regenerative Medicine ’s #CGMesa24 this week in #Phoenix , AZ. We’re eager to listen to all the expert-led panels and presentations and look forward to networking with everyone and exploring ways we can partner to help advance cell and gene therapies and help make them increasingly accessible to the patients who need them. If you’re attending, don’t miss the chance to connect with us! Let’s collaborate and work together to push the boundaries of cell and gene therapy. Please message us here or in the partnering app or request a meeting on our website here https://lnkd.in/eDHhWZac #CGMesa24 #CellAndGeneTherapy #CellTherapy , #GeneTherapy

ADVA

COM:ADVANCEDTHERAPIES

WuXi Advanced Therapies

name

homepage url

country

linkedin url

crunchbase url

sector

industry

Description

competitor of

Metrics